NCT00160030已完成2 期
Phase II Study Comparing Radiochemotherapy With the Folfox 4 Regimen Versus Radiochemotherapy With 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Esophageal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 97
- 试验地点
- 1
- 主要终点
- Percentage of patients having completed the full treatment and Endoscopic complete response rate
研究概览
简要总结
The primary objectives of this study are to assess the feasibility (completion of full treatment) in both arms and to assess endoscopic complete response rate in both arms.
The secondary objective of this study is to assess the toxicity profile of each arm using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) scale (V.3).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with:
- •Histologically proven adenocarcinoma, squamous cell or adenosquamous carcinoma of the esophagus
- •Inoperable esophageal carcinoma (disease status: any T, N0 or N1, M0 or M1a) or surgical contraindication conditions
- •No prior treatment for esophageal cancer (surgery, laser, chemo- or radiotherapy)
- •Oesophageal dilatation is allowed before or during the treatment, but prior esophageal prosthesis is not allowed
- •Peripheral neuropathy <= NCI-CTC grade 1
- •Age >= 18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2
- •Sufficient (oral or with gastrostomy) calorific intake (> 1000 Kcal/m2/day)
- •Life expectancy >= 3 months
- •Adequate bone marrow reserve, normal renal and liver functions:
- •Neutrophil count >= 1500/mm³
- •Platelet count >= 100,000/mm³
- •Hemoglobin >= 10 g/dl (after transfusion, if necessary)
- •Creatinine levels <= 1.5 x the upper normal limit of institutional values (ULN)
- •Total bilirubin level < 1.5 x ULN
- •ALT/AST < 2.5 x ULN
- •Prothrombin time >= 60%
- •Laboratory values obtained the week preceding study entry
- •Signed informed consent (prior to all study procedures)
- •Start of treatment within 28 days of inclusion.
排除标准
- •Metastatic disease except for third upper or cervical esophagus tumor with regional nodes, or third lower esophagus tumor with celiac nodes (M1a)
- •Multiple carcinomas of the esophagus
- •Small cell or undifferentiated carcinoma of the esophagus
- •Complete dysphagia (grade 4 NCI-CTC); patient with exclusive parenteral nutrition.
- •Weight loss > 20% normal body weight
- •Pregnant or breast-feeding women
- •Fertile patient not using adequate contraception
- •Peripheral sensitive neuropathy with functional impairment
- •Auditory disorders
- •History of prior malignancies (other than cured non melanoma skin cancer, cured cervical carcinoma in situ or stage I or II node negative head and neck cancer cured > 3 years ago)
- •Prior cervical, thoracic and abdominal radiotherapy with field overlapping the proposed oesophageal radiotherapy field
- •Tracheo-oesophageal fistula or invasion of the tracheo-bronchial tree
- •Previous myocardial infarction (inferior or equal to 6 months). Patients with a previous myocardial infarction superior to 6 months, could be included only if: no transient ischemia is shown by thallium myocardial scintigraphy and favourable advice for chemotherapy is obtained from a cardiologist.
- •Other serious illness or medical conditions (such as symptomatic coronary disease, left ventricular failure or uncontrolled infection)
- •Arterial disease stage II to IV according to the Leriche and Fontaine classification
- •Treatment with any other experimental drugs or participation in another clinical trial within 30 days of study screening
- •Concurrent treatment with any other anti-cancer therapy
- •Concurrent treatment with phenytoin and yellow fever vaccine; geographical, social or psychological circumstances preventing regular follow-up.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Experimental
干预措施: FOLFOX 4 (Drug)
2
Active Comparator
干预措施: 5-FU / Cisplatin (Drug)
结局指标
主要结局
Percentage of patients having completed the full treatment and Endoscopic complete response rate
时间窗: at the end of the study
次要结局
- Toxicity profile (NCI-CTC).(evaluated each week)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT00817258Fudan University37
已完成
1 期
Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast CancerBreast CancerNCT00724386University of Chicago26
Unknown
2 期
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeNCT01667302Fudan University30
撤回
2 期
Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT01432314Asan Medical Center
已完成
2 期
Cyberknife Radiosurgery for Locally Advanced Pancreatic CancerPancreatic CancerNCT00233415Stanford University100